Challenges for the registration of vaccines in emerging countries: Differences in dossier requirements, application and evaluation processes.

Abstract:

:The divergence of regulatory requirements and processes in developing and emerging countries contributes to hamper vaccines' registration, and therefore delay access to high-quality, safe and efficacious vaccines for their respective populations. This report focuses on providing insights on the heterogeneity of registration requirements in terms of numbering structure and overall content of dossiers for marketing authorisation applications for vaccines in different areas of the world. While it also illustrates the divergence of regulatory processes in general, as well as the need to avoid redundant reviews, it does not claim to provide a comprehensive view of all processes nor existing facilitating mechanisms, nor is it intended to touch upon the differences in assessments made by different regulatory authorities. This report describes the work analysed by regulatory experts from vaccine manufacturing companies during a meeting held in Geneva in May 2017, in identifying and quantifying differences in the requirements for vaccine registration in three aspects for comparison: the dossier numbering structure and contents, the application forms, and the evaluation procedures, in different countries and regions. The Module 1 of the Common Technical Document (CTD) of 10 countries were compared. Modules 2-5 of the CTDs of two regions and three countries were compared to the CTD of the US FDA. The application forms of eight countries were compared and the registration procedures of 134 importing countries were compared as well. The analysis indicates a high degree of divergence in numbering structure and content requirements. Possible interventions that would lead to significant improvements in registration efficiency include alignment in CTD numbering structure, a standardised model-application form, and better convergence of evaluation procedures.

journal_name

Vaccine

journal_title

Vaccine

authors

Dellepiane N,Pagliusi S,Registration Experts Working Group.

doi

10.1016/j.vaccine.2018.03.049

subject

Has Abstract

pub_date

2018-06-07 00:00:00

pages

3389-3396

issue

24

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(18)30405-5

journal_volume

36

pub_type

相关文献

VACCINE文献大全
  • Evaluation of novel Brucella melitensis unmarked deletion mutants for safety and efficacy in the goat model of brucellosis.

    abstract::Pregnant goats were employed to assess unmarked deletion mutant vaccine candidates BMDeltaasp24, BMDeltacydBA, and BMDeltavirB2, as the target host species naturally infected with Brucella melitensis. Goats were assessed for the degree of pathology associated with the vaccine strains as well as the protective immunity...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.04.005

    authors: Kahl-McDonagh MM,Elzer PH,Hagius SD,Walker JV,Perry QL,Seabury CM,den Hartigh AB,Tsolis RM,Adams LG,Davis DS,Ficht TA

    更新日期:2006-06-12 00:00:00

  • Population-based evaluation of type-specific HPV prevalence among women in British Columbia, Canada.

    abstract:BACKGROUND:British Columbia (BC) introduced a school-based HPV vaccine program in September 2008. As part of the HPV vaccine program evaluation, we determined the type-specific HPV prevalence in a population-based sample of women presenting for routine cervical cancer screening in the province. METHODS:From June 2010 ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.09.085

    authors: Ogilvie GS,Cook DA,Taylor DL,Rank C,Kan L,Yu A,Mei W,van Niekerk DJ,Coldman AJ,Krajden M

    更新日期:2013-02-04 00:00:00

  • Antigen-specific IgA and IgG responses in calves inoculated intranasally with ovalbumin encapsulated in poly(DL-lactide-co-glycolide) microspheres.

    abstract::The immunogenicity of proteins encapsulated in poly(DL-lactide-co-glycolide) (PLG) microspheres has not been investigated to any extent in large animal models. In this study, IgG and IgA responses to ovalbumin (OVA), encapsulated in microspheres was investigated following intranasal inoculation into calves. Scanning e...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(03)00432-8

    authors: Kavanagh OV,Earley B,Murray M,Foster CJ,Adair BM

    更新日期:2003-10-01 00:00:00

  • Combination vaccines in the South African setting.

    abstract::The number of vaccines available and included as part of the national immunization schedules, has increased significantly over the past few decades. This impacts on patient/parent compliance and creates a challenge for health care providers for implementation of schedules necessitating training and infrastructure impr...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2012.05.001

    authors: Visser A,Hoosen A

    更新日期:2012-09-07 00:00:00

  • Outer membrane PhoE protein of Escherichia coli as a carrier for foreign antigenic determinants: immunogenicity of epitopes of foot-and-mouth disease virus.

    abstract::Outer membrane protein PhoE of Escherichia coli was used for the expression of antigenic determinants of foot-and-mouth disease virus. Five hybrid PhoE proteins were constructed containing different combinations of two antigenic determinants of VP1 protein of the virus. The hybrid proteins were expressed in two E. col...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(90)90184-n

    authors: Agterberg M,Adriaanse H,Lankhof H,Meloen R,Tommassen J

    更新日期:1990-02-01 00:00:00

  • Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques.

    abstract::Plasmid DNA is a promising vaccine platform that has been shown to be safe and able to be administered repeatedly without vector interference. Enhancing the potency of DNA vaccination through co-delivery of molecular adjuvants is one strategy currently under investigation. Here we describe the use of the novel chemoki...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.10.095

    authors: Kraynyak KA,Kutzler MA,Cisper NJ,Khan AS,Draghia-Akli R,Sardesal NY,Lewis MG,Yan J,Weiner DB

    更新日期:2010-02-23 00:00:00

  • Potential of KM+ lectin in immunization against Leishmania amazonensis infection.

    abstract::In the present study we evaluated Canavalia brasiliensis (ConBr), Pisum arvense (PAA) and Artocarpus integrifolia (KM+) lectins as immunostimulatory molecules in vaccination against Leishmania amazonensis infection. Although they induced IFN-gamma production, the combination of the lectins with SLA antigen did not lea...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.11.067

    authors: Teixeira CR,Cavassani KA,Gomes RB,Teixeira MJ,Roque-Barreira MC,Cavada BS,da Silva JS,Barral A,Barral-Netto M

    更新日期:2006-04-05 00:00:00

  • Mutant influenza A virus nucleoprotein is preferentially localized in the cytoplasm and its immunization in mice shows higher immunogenicity and cross-reactivity.

    abstract::Many influenza vaccines targeted to hemagglutinin (HA) show efficient immunogenicity for protecting subjects against influenza virus infection. Major antigenic changes to HA molecules can help influenza virus to develop resistance against HA-targeted vaccines. DNA vaccines encoding conserved antigens protect animals a...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.02.074

    authors: Ohba K,Yoshida S,Zahidunnabi Dewan M,Shimura H,Sakamaki N,Takeshita F,Yamamoto N,Okuda K

    更新日期:2007-05-22 00:00:00

  • Priority allocation of pandemic influenza vaccines in Australia - Recommendations of 3 community juries.

    abstract:BACKGROUND:Pandemic planning has historically been oriented to respond to an influenza virus, with vaccination strategy being a key focus. As the current COVID-19 pandemic plays out, the Australian government is closely monitoring progress towards development of SARS-CoV2 vaccines as a definitive intervention. However,...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.12.010

    authors: Degeling C,Williams J,Carter SM,Moss R,Massey P,Gilbert GL,Shih P,Braunack-Mayer A,Crooks K,Brown D,McVernon J

    更新日期:2021-01-08 00:00:00

  • The immune response to a two-dose schedule of quadrivalent HPV vaccine in 9-13 year-old girls: Is it influenced by age, menarche status or body mass index?

    abstract::HPV vaccines are highly immunogenic. A two-dose schedule for 9-14 year-old is recommended. However, no data exist regarding the impact of age, menarche status and body mass index (BMI) on the immune response to a two-dose schedule. In this post-hoc analysis, we present antibody titers to HPV6/11/16/18 in 9-13 year-old...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2019.09.089

    authors: Sauvageau C,Gilca V,Donken R,Fan SY,Ogilvie G,Dobson S

    更新日期:2019-11-20 00:00:00

  • HPV vaccine for adolescent males: acceptability to parents post-vaccine licensure.

    abstract::We examined mothers' willingness to get their adolescent sons HPV vaccine. In December 2009, 2 months after approval of HPV vaccine for males, we surveyed a national sample of mothers with sons aged 9-18 (n=406). More mothers were definitely or probably willing to get their sons HPV vaccine if the vaccine were free (4...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.06.114

    authors: Reiter PL,McRee AL,Gottlieb SL,Brewer NT

    更新日期:2010-08-31 00:00:00

  • Threshold cost-effectiveness analysis for a therapeutic vaccine against HPV-16/18-positive cervical intraepithelial neoplasia in the Netherlands.

    abstract::In this study, the potential price for a therapeutic vaccine against Human Papilloma Virus (HPV)-16 & 18 (pre)-malignant cervical lesions is examined. A decision tree model was built in the context of the new Dutch cervical cancer-screening program and includes a primary test for the presence of HPV. Based on data of ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2016.10.019

    authors: Luttjeboer J,Setiawan D,Cao Q,Cahh Daemen T,Postma MJ

    更新日期:2016-12-07 00:00:00

  • Changes in the seroepidemiology of hepatitis B infection in Catalonia 1989-1996.

    abstract::The objective of this study was to investigate the prevalence of hepatitis B markers in a representative sample of 2142 subjects in Catalonia, Spain, and to compare it with previous studies. Multiple logistical regression analysis was carried out to determine variables associated with the markers studied. The prevalen...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(00)00028-1

    authors: Domínguez A,Bruguera M,Vidal J,Plans P,Salleras L

    更新日期:2000-05-08 00:00:00

  • Serine proteases of Leishmania amazonensis as immunomodulatory and disease-aggravating components of the crude LaAg vaccine.

    abstract::We previously demonstrated that intradermal and intramuscular vaccination with Leishmania amazonensis promastigote antigens (LaAg) increases the susceptibility of BALB/c mice to cutaneous leishmaniasis. In this study, we investigated the role played by serine and cysteine proteases as disease-promoting components of L...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.04.109

    authors: de Matos Guedes HL,Pinheiro RO,Chaves SP,De-Simone SG,Rossi-Bergmann B

    更新日期:2010-07-26 00:00:00

  • Protection capability of recombinant plasmid DNA vaccine containing VP2 gene of very virulent infectious bursal disease virus in chickens adjuvanted with CpG oligodeoxynucleotide.

    abstract::In the present study the efficacy of recombinant plasmids DNA vaccine encoding VP2 gene of very virulent strain of infectious bursal disease virus (vvIBDV) isolated from Pakistan was investigated with or without coadministration of cytocine-phosphate-guanine oligodeoxynucleotide (CpG ODN) to protect the chickens again...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.03.016

    authors: Mahmood MS,Siddique M,Hussain I,Khan A,Mansoor MK

    更新日期:2006-05-29 00:00:00

  • Assessment of influenza vaccine effectiveness in a sentinel surveillance network 2010-13, United States.

    abstract:BACKGROUND:Influenza vaccines are now widely used to reduce the burden of annual epidemics of influenza virus infections. Influenza vaccine effectiveness (VE) is monitored annually to determine VE against each season's circulating influenza strains in different groups such as children, adults and the elderly. Few prosp...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.11.016

    authors: Cowling BJ,Feng S,Finelli L,Steffens A,Fowlkes A

    更新日期:2016-01-02 00:00:00

  • Uptake of varicella vaccine--a cross sectional survey of parental attitudes to nationally recommended but unfunded varicella immunisation.

    abstract::The aim of this study was to assess the uptake of varicella vaccine in South Australian children under circumstances where varicella immunisation is recommended, but is not funded by Government. The study examined the main reasons that determined a parent's decision whether or not to have their child immunised with va...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.05.033

    authors: Marshall H,Ryan P,Roberton D

    更新日期:2005-11-16 00:00:00

  • A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig model.

    abstract::Lassa fever remains the most imported viral haemorrhagic fever in Europe and is responsible for 5000 deaths per year throughout Western Africa. There is no vaccine and treatment is often ineffective. We have developed a vaccine based on modified Vaccinia Ankara expressing the nucleoprotein from Lassa virus (MVALassaNP...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.07.023

    authors: Kennedy EM,Dowall SD,Salguero FJ,Yeates P,Aram M,Hewson R

    更新日期:2019-08-23 00:00:00

  • Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain.

    abstract::Two rotavirus vaccines have been available since 2006. This study evaluates the effectiveness of these vaccines using a test-negative case-control design in Navarre, Spain. We included children 3-59 months of age who sought medical care for gastroenteritis and for whom stool samples were taken between January 2008 and...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.11.071

    authors: Castilla J,Beristain X,Martínez-Artola V,Navascués A,García Cenoz M,Alvarez N,Polo I,Mazón A,Gil-Setas A,Barricarte A

    更新日期:2012-01-11 00:00:00

  • Global distribution of group A rotavirus strains in horses: a systematic review.

    abstract::Group A rotavirus (RVA) is a major cause of diarrhea and diarrhea-related mortality in foals in parts of the world. In addition to careful horse farm management, vaccination is the only known alternative to reduce the RVA associated disease burden on horse farms. The precise evaluation of vaccine effectiveness against...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2013.08.045

    authors: Papp H,Matthijnssens J,Martella V,Ciarlet M,Bányai K

    更新日期:2013-11-19 00:00:00

  • Process development for the mass production of Ehrlichia ruminantium.

    abstract::This work describes the optimization of a cost-effective process for the production of an inactivated bacterial vaccine against heartwater and the first attempt to produce the causative agent of this disease, the rickettsia Ehrlichia ruminantium (ER), using stirred tanks. In vitro, it is possible to produce ER using c...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.08.109

    authors: Marcelino I,Sousa MF,Veríssimo C,Cunha AE,Carrondo MJ,Alves PM

    更新日期:2006-03-06 00:00:00

  • Modelling the epidemiological impact of rotavirus vaccination in Germany--a Bayesian approach.

    abstract:BACKGROUND:Rotavirus (RV) infection is the primary cause of severe gastroenteritis in children aged <5 years in Germany and worldwide. In 2013 the German Standing Committee on Vaccination (STIKO) developed a national recommendation for routine RV-immunization of infants. To support informed decision-making we predicted...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.06.090

    authors: Weidemann F,Dehnert M,Koch J,Wichmann O,Höhle M

    更新日期:2014-09-08 00:00:00

  • Specificity of anti-Nef antibodies produced in mice immunized with DNA encoding the HIV-1 nef gene product.

    abstract::Mice immunized with plasmid DNA encoding Nef regulatory protein of human immunodeficiency virus type 1 developed high levels of anti-Nef antibodies. After 4 intramuscular injections of 100 microg plasmid DNA, anti-Nef antibodies reached titers up to 2 x 10(4). A significant specific antibody response was maintained fo...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(99)00203-0

    authors: Moureau C,Moynier M,Kavsan V,Montagnier L,Bahraoui E

    更新日期:1999-09-01 00:00:00

  • Chapter 26: Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries.

    abstract::The costs of developing and producing new-generation vaccines have increased compared to many of the older, "traditional" vaccines because of new technologies and regulatory requirements. While the public sector often supports basic research costs, private manufacturers are usually responsible for the investments in p...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2006.05.042

    authors: Batson A,Meheus F,Brooke S

    更新日期:2006-08-31 00:00:00

  • Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects.

    abstract::We previously observed that a detoxified Escherichia coli O111, Rc chemotype J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) vaccine protected animals from experimental lethal sepsis when immune antibodies were given passively as treatment at the onset of fever or when vaccine was giv...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章

    doi:10.1016/s0264-410x(03)00483-3

    authors: Cross AS,Opal SM,Palardy JE,Drabick JJ,Warren HS,Huber C,Cook P,Bhattacharjee AK

    更新日期:2003-11-07 00:00:00

  • Measles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogens.

    abstract::Helicobacter pylori neutrophil-activating protein (NAP) is a toll-like receptor 2 (TLR2) agonist and potent immunomodulator inducing Th1-type immune response. Here we present data about characterization of the humoral immune response against NAP-tagged antigens, encoded by attenuated measles virus (MV) vector platform...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.07.085

    authors: Iankov ID,Federspiel MJ,Galanis E

    更新日期:2013-10-01 00:00:00

  • Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants.

    abstract::An effective vaccination strategy against human immunodeficiency virus type 1 (HIV-1) should include the induction of potent cellular immune responses against conserved HIV-1 antigens. We have generated five replication competent recombinant influenza viruses (rFlu/SIV Gag nos. 1-5) expressing different portions of Ga...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(02)00781-8

    authors: Nakaya Y,Zheng H,García-Sastre A

    更新日期:2003-05-16 00:00:00

  • Vaccines in the era of genomics: the pneumococcal challenge.

    abstract::In this review we aim to provide the reader with an understanding of the capsular-based complexity of Streptococcus pneumoniae, one of the main limitations to current vaccine development. We then discuss the need for a new vaccine strategy based on proteic antigen candidates discovered in silico. Describing specifical...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2007.01.065

    authors: Barocchi MA,Censini S,Rappuoli R

    更新日期:2007-04-20 00:00:00

  • Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine.

    abstract::A post hoc analysis was performed using combined data from two Phase I tolerability/immunogenicity studies of monovalent human papillomavirus type 11 (HPV11) or HPV16 L1 virus-like particle (VLP) vaccines. The goal was to determine if the HPV16 L1 VLP vaccine protected against HPV16 infection. Vaccine or placebo was g...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2003.11.059

    authors: Brown DR,Fife KH,Wheeler CM,Koutsky LA,Lupinacci LM,Railkar R,Suhr G,Barr E,Dicello A,Li W,Smith JF,Tadesse A,Jansen KU

    更新日期:2004-07-29 00:00:00

  • Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66.

    abstract::SPf66 is the first chemically synthesised vaccine to elicit a partial protective immune response against malaria. The aluminium hydroxide (alum)-adsorbed SPf66 vaccine is weakly immunogenic and of poor to moderate efficacy in humans. To investigate the possibility of improving SPf66 vaccine immunogenicity, a delivery ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(01)00192-x

    authors: Rosas JE,Hernández RM,Gascón AR,Igartua M,Guzman F,Patarroyo ME,Pedraz JL

    更新日期:2001-08-14 00:00:00